Press Releases

15 November 2021

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

Read more
12 October 2021

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

Read more
16 September 2021

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Read more
21 July 2021

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

Read more
WordPress Cookie Plugin by Real Cookie Banner